EFFICACY AND SAFETY OF COMBINATION TREATMENT WITH ABATACEPT AND METHOTREXATE AND MONOTHERAPY WITH METHOTREXATE IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/vsp.v11i6.500
Abstract
The results of efficacy and safety study of abatacept and methotrexate combination therapy (n=12) in comparison with methotrexate monotherapy (n =41) in patients with polyarticular juvenile idiopathic arthritis at the age of 4–17 years old are shown in this article. The duration of the observation was 1 year. Abatacept was introduced at a dose of 10 mg/kg at 1st, 2d and then — every 4th week. In 48 weeks clinical remission and decrease of laboratory markers of activity was registered in 35% of patients treated with abatacept and methotrexate and in 16% of patients treated only with methotrexate.
About the Authors
V. A. Kel'tsev
Samara State Medical University
Russian Federation
Russian Federation
L. I. Grebenkina
Samara State Medical University
Russian Federation
Russian Federation
N. S. Pryanichkova
Samara State Medical University
Russian Federation
Russian Federation
S. А. Gorunov
Samara State Medical University
Russian Federation
Russian Federation
N. V. Lagoda
Samara State Medical University
Russian Federation
Russian Federation
References
1. CassidyJ., Petty R. (eds). Textbook of paediatric rheumatology. N.-Y.: Churchill Livigstone. 2002.
2. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007.
3. Кельцев В. А. Ювенильный идиопатический артрит. Самара: Содружество. 2005. 214 с.
4. Кельцев В. А. Клиническая артрология (руководство для вра- чей). Самара: Содружество. 2010. 616 с.
5. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294: 1671–1684.
6. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
7. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity. 2008; 41: 224–229.
8. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Аутоиммунные заболевания. М. 2002. 127 с.
9. Насонов Е. Л., Каратеев Д. Е. Применение блокатора кости- муляции Т лимфоцитов абатацепта при ревматоидном артрите. Научно-практическая ревматология. 2010; 4 (2): 9–27.
10. Амирджанова В. Н., Насонов Е. Л. Абатацепт и качество жизни больных ревматоидным артритом (результаты международных исследований). Научно-практическая ревматология. 2010; 4 (2): 32–35.
11. Никишина И. П. Применение абатацепта в лечении ювенильного артрита. Научно-практическая ревматология. 2010; 4 (2): 42–45.
12. Бзарова Т. М., Алексеева Е. И., Фетисова А. Н., Клочкова О. А. Опыт применения абатацепта у больной серопозитивным вари- антом идиопатического ювенильного артрита. Вопр. совр. пед. 2012; 2: 155–162.
13. Насонов Е. Л. Новые аспекты фармакоторапии ревматоидно- го артрита — блокада костимуляции Т лимфоцитов. РМЖ. 2009; 17 (3): 2–7.
14. Davies R., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.
15. Linsley P. S., Brady W., Urnes M., Grosmaire L. S., Damle N. K., Ledbetter J. A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.
16. Webb L. M., Walmsley M. J., Feldmаnn M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.
17. Moreland L. W., Alten R., Van den Bosch F. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, doubleblind, placebo-controlled clinical trial evaluating CTLA-4lg and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.
18. Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. N. Engl. J. Med. 2003; 349: 1907–1915.
19. KremerJ. M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., Steinfeld S., Tindall E., Becker J. C., Li T., Nuamah I. F., Aranda R., Moreland L. W. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.
20. Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.
Review
For citations:
Kel'tsev V.A., Grebenkina L.I., Pryanichkova N.S., Gorunov S.А., Lagoda N.V. EFFICACY AND SAFETY OF COMBINATION TREATMENT WITH ABATACEPT AND METHOTREXATE AND MONOTHERAPY WITH METHOTREXATE IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Current Pediatrics. 2012;11(6):103-109. (In Russ.) https://doi.org/10.15690/vsp.v11i6.500
Views:
766
Email this article 
